CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grant, S.
Right arrow Articles by Jarvis, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grant, S.
Right arrow Articles by Jarvis, W. D.

Cell Growth & Differentiation, Vol 7, Issue 5 603-613, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67)

S Grant, AJ Freemerman, MJ Birrer, HA Martin, AJ Turner, E Szabo, J Chelliah and WD Jarvis
Department of Medicine, Medical College of Virginia, Richmond 23298, USA.

The proto-oncogene c-jun encodes a component of the AP-1 transcription-activating complex and has been implicated in the regulation of diverse cellular processes, including cell proliferation, differentiation, transformation, and most recently, apoptosis. We have used a U937 monocytic leukemia cell line stably expressing a c-jun dominant-negative, transactivation-domain deletion mutant (TAM67) to assess the role of c-jun in apoptotic events induced by exposure to the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C). Mutant cells produce a truncated M(r) 29,000 protein that interferes with the function of normal c-Jun (and c-Fos) proteins through a quenching mechanism. Parental U937, cells expressing TAM67, and cells carrying only the empty vector (pMM) were exposed to ara-C for 6 h, and apoptosis was monitored by cell morphology as well as qualitative and quantitative assays of DNA damage. No differences in apoptosis could be detected between the three cell lines at any of the ara-C concentrations evaluated. In addition, ara-C concentrations > or = 1.0 x 10(-6) M were equally inhibitory to the clonogenic growth of U937 and TAM67-expressing cells. In contrast, lower concentrations of ara-C (i.e., < 5.0 x 10(-7) M) were significantly less inhibitory to mutant U937 cell colony formation than to their parental counterparts. The reduced sensitivity of TAM67-expressing cells to low concentrations of ara-C could not be attributed to biochemical or cytokinetic factors, since the two cell lines were indistinguishable with respect to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) formation, ara-CTP:dCTP ratios, and S-phase fraction. However, a significantly lower percentage of TAM67-expressing cells exposed to submicromolar concentrations of ara-C exhibited features associated with a differentiated monocytoid phenotype (i.e., increased plastic adherence and CD11b expression) compared to their parental counterparts. Lower concentrations of ara-C were also significantly less effective in decreasing the percentage of S-phase cells and in down-regulating c-myc mRNA levels in the mutant line, events associated with induction of leukemic cell differentiation. Finally, ara-C-induced up-regulation of c-jun message and protein was markedly attenuated in TAM67-expressing cells, findings consistent with a c-jun dominant-negative model. Collectively, these findings suggest that dysregulation of c-jun in U937 cells antagonizes low-dose ara-C-mediated cellular maturation but does not prevent higher concentration of this agent from triggering apoptosis. They also raise the possibility that separate aspects of the antiproliferative actions of ara-C may be differentially regulated by c-jun.


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
W.-H. Lee, M.-H. Chung, Y.-H. Tsai, J.-L. Chang, and H.-M. Huang
Interferon-{gamma} suppresses activin A/NF-E2 induction of erythroid gene expression through the NF-{kappa}B/c-Jun pathway
Am J Physiol Cell Physiol, February 15, 2014; 306(4): C407 - C414.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Dasmahapatra, M. Rahmani, P. Dent, and S. Grant
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism
Blood, January 1, 2006; 107(1): 232 - 240.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Yu, S. Wang, P. Dent, and S. Grant
Sequence-Dependent Potentiation of Paclitaxel-Mediated Apoptosis in Human Leukemia Cells by Inhibitors of the Mitogen-Activated Protein Kinase Kinase/Mitogen-Activated Protein Kinase Pathway
Mol. Pharmacol., July 1, 2001; 60(1): 143 - 154.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Vrana and S. Grant
Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade
Blood, April 1, 2001; 97(7): 2105 - 2114.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Sampath and W. Plunkett
The Role of c-jun Kinase in the Apoptotic Response to Nucleoside Analogue-induced DNA Damage
Cancer Res., November 1, 2000; 60(22): 6408 - 6415.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
W. D. Jarvis, C. R. Johnson, F. A. Fornari, J. S. Park, P. Dent, and S. Grant
Evidence That the Apoptotic Actions of Etoposide Are Independent of c-Jun/Activating Protein-1-Mediated Transregulation
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1384 - 1392.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
W. D. Jarvis, F. A. Fornari Jr., R. M. Tombes, R. K. Erukulla, R. Bittman, G. K. Schwartz, P. Dent, and S. Grant
Evidence for Involvement of Mitogen-Activated Protein Kinase, Rather than Stress-Activated Protein Kinase, in Potentiation of 1-{beta}-D-Arabinofuranosylcytosine-Induced Apoptosis by Interruption of Protein Kinase C Signaling
Mol. Pharmacol., November 1, 1998; 54(5): 844 - 856.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Zagariya, S. Mungre, R. Lovis, M. Birrer, S. Ness, B. Thimmapaya, and R. Pope
Tumor Necrosis Factor Alpha Gene Regulation: Enhancement of C/EBPbeta -Induced Activation by c-Jun
Mol. Cell. Biol., May 1, 1998; 18(5): 2815 - 2824.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. C. Maroney, M. A. Glicksman, A. N. Basma, K. M. Walton, E. Knight Jr, C. A. Murphy, B. A. Bartlett, J. P. Finn, T. Angeles, Y. Matsuda, et al.
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway
J. Neurosci., January 1, 1998; 18(1): 104 - 111.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
H. Seimiya, T. Mashima, M. Toho, and T. Tsuruo
c-Jun NH2-terminal Kinase-mediated Activation of Interleukin-1{beta} Converting Enzyme/CED-3-like Protease during Anticancer Drug-induced Apoptosis
J. Biol. Chem., February 14, 1997; 272(7): 4631 - 4636.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.